Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Emerging therapeutics in the management of COVID-19
Asim Kichloo, Department of Internal Medicine, Samaritan Medical Center, Watertown, NY 13601, United States
Michael Albosta, Mohamed Mohamed, Zain El-Amir, Shakeel Jamal, Department of Internal Medicine, Central Michigan University, Saginaw, MI 48602, United States
Akshay Kumar, Department of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA 15260, United States
Michael Aljadah, Deparment of Internal Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, United States
Farah Wani, Department of Family Medicine, Samaritan Medical Center, Watertown, NY 13601, United States
Jagmeet Singh, Department of Transplant Nephrology, Geisinger Commonwealth School of Medicine, Sayre, PA 18510, United States
Akif Kichloo, Department of Anesthesiology and Critical Care, Saraswathi Institue of Medical Sciences, Uttar Pradesh 245304, India
Author contributions: Kichloo A, Albosta M, Kumar A and Aljadah M are credited with substantial contribution to the design of the work, literature review of all the sections discussed, the revision of critically important intellectual content, final approval of the published version, and agreement of accountability for all aspects of the work; Mohamed M, El-Amir Z, Wani F and Jamal S are credited with substantial acquisition, analysis, and extraction of the literature reviewed for the manuscript, drafting the manuscript, final approval of the version to be published, and agreement of accountability for all aspects of the work; Singh J and Kichloo A are credited with the revision of critically important intellectual content and final approval of the version to be published, and agreement of accountability for all aspects of the work.
Conflict-of-interest statement: The authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Michael Albosta, MD, Doctor, Department of Internal Medicine, Central Michigan University, 1632 Stone Street, Saginaw, MI 48602, United States.
Received: September 18, 2020
Peer-review started: September 18, 2020
First decision: December 1, 2020
Revised: December 2, 2020
Accepted: December 13, 2020
Article in press: December 13, 2020
Published online: January 25, 2021
Processing time: 124 Days and 15.7 Hours
Peer-review started: September 18, 2020
First decision: December 1, 2020
Revised: December 2, 2020
Accepted: December 13, 2020
Article in press: December 13, 2020
Published online: January 25, 2021
Processing time: 124 Days and 15.7 Hours
Core Tip
Core Tip: As coronavirus disease 2019 continues to affect the global community, researchers are working diligently to determine the efficacy of therapeutic agents to fight this virus in clinical trials. Currently, there is a lack of published literature that comprehensively discusses all of the therapeutic agents under investigation. In this manuscript, we provide readers with a thorough and comprehensive evaluation of the current state of therapeutics including the proposed mechanisms of action, pharmacokinetics, recommended dosages, adverse effects, and efficacy data from clinical trials.